Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Jackson, Mississippi 39216


In patients with at least moderate persistent allergic asthma controlled with inhaled steroids, omalizumab (administered per US product label), when compared to placebo, will provide the participants with significantly improved tolerability of specific allergen immunotherapy (allergy shots) administered per a cluster schedule(rapid build up method).

Study summary:

Omalizumab is an FDA approved anti-IgE drug used to treat allergic asthma. This study is designed to give omalizumab 13 weeks prior to administering rapid build up of specific allergy shot, with an overlap of omalizumab and cluster therapy for 3 weeks. The cluster therapy will take 4 week to complete with maintenance dosage lasting an additional 6 weeks.


Inclusion Criteria: - clinical diagnosis and history of moderate persistent allergic asthma - body weight >/= 20kg and </= 150kg - Total serum IgE >/= 30 and </= 700IU/mL - on a stable asthma treatment including corticosteroids for the preceding 4 weeks - non smoker for at least 1 year prior to visit 1 Exclusion Criteria: - patients with severe asthma - history of immunotherapy to any allergen within the past 3 years - history of anaphylactic allergic reaction - upper respiratory tract infection



Primary Contact:

Principal Investigator
Gailen D. Marshall, MD/PhD
University of Mississippi Medical Center

Backup Contact:


Location Contact:

Jackson, Mississippi 39216
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.